Pembrolizumab and Paclitaxel in HR+/HER2- Breast Cancer with HER2-Enriched or Basal-Like Subtypes. Conte B, Braso-Maristany F, Pascual T, Hernando C, et al. Clin Cancer Res 2026 Jan 22. doi: 10.1158/1078-0432.CCR-25-2570.

Read + Share

Amedeo Smart

Independent Medical Education

Conte B, Braso-Maristany F, Pascual T, Hernando C, et al. Pembrolizumab and Paclitaxel in HR+/HER2- Breast Cancer with HER2-Enriched or Basal-Like Subtypes. Clin Cancer Res 2026 Jan 22. doi: 10.1158/1078-0432.CCR-25-2570.
PMID: 41569440